Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE MKT: ELMD) is a Minnesota-based company recognized as an innovative leader in the development, manufacture, and worldwide distribution of the SmartVest® Airway Clearance System. This patented system leverages High-Frequency Chest Wall Oscillation (HFCWO), offering a well-tolerated alternative to traditional chest physiotherapy (CPT). The system is designed to deliver effective and comfortable airway clearance treatment for patients suffering from the consequences of retained secretions.
Clinically proven, HFCWO technology helps clear the lungs of excess mucus, thereby improving lung function and reducing infections for individuals with conditions such as atelectasis, COPD, bronchiectasis, neuromuscular diseases, and cystic fibrosis. Electromed, Inc. is accredited by the Joint Commission and holds ISO 13485:2003 and ISO 9001:2008 certifications, demonstrating their commitment to quality and safety.
The SmartVest System consists of a programmable air pulse generator, a therapy garment worn over the upper body, and a connecting hose. Together, these components provide a safe, comfortable, and effective airway clearance therapy that enhances the quality of life for patients with compromised pulmonary function.
Electromed, Inc. continuously strives for excellence and compassionate service. Their products are designed with patient comfort and usability in mind, ensuring that users receive the best possible care. With a global reach, the company is dedicated to improving respiratory health for patients worldwide.
Stay updated with the latest developments, achievements, and financial performance of Electromed, Inc. by following their news and updates. The company's ongoing projects and partnerships underscore its commitment to innovation and excellence in the field of airway clearance therapy.
Electromed, Inc. (NYSE American: ELMD) announced that Kathleen Skarvan, President and CEO, and Michelle Wirtz, Interim CFO, will participate in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022. They will also be available for one-on-one investor meetings on August 10, 2022. Electromed specializes in airway clearance technologies, including the SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function. The company is based in New Prague, Minnesota, and was founded in 1992.
Electromed, Inc. (NYSE American: ELMD) released a report detailing findings from a third-party clinical study presented at the American Thoracic Society International Conference in San Francisco. The study demonstrated that patients using high frequency chest wall oscillation (HFCWO) therapy showed improved health outcomes and a reduction in healthcare resource utilization (HCRU), including lower medication usage. The analysis focused on non-cystic fibrosis bronchiectasis patients, emphasizing HFCWO's effectiveness in enhancing patient care and reducing hospitalizations.
Electromed, Inc. (NYSE American: ELMD) reported a 15.4% revenue growth in its fiscal Q3 2022, achieving net revenues of $10.1 million. This increase was primarily driven by home care revenues of $9.0 million. Gross profit was 76.4% of net revenues, supported by higher Medicare pricing and operational efficiencies. Net income rose to $0.6 million, or $0.07 per diluted share, compared to the previous year's $0.2 million. The company announced a CFO transition and appointed Christopher Holland as Chief Commercial Officer to bolster growth initiatives.
Electromed, Inc. (AMEX: ELMD), a leader in airway clearance technologies, will participate in the Sidoti May Virtual Micro Cap Investor Conference on May 11-12, 2022. Kathleen Skarvan, President and CEO, and Mike MacCourt, CFO, will be available for one-on-one meetings during the event.
The group presentation by Electromed is scheduled for May 12 at 10:00 AM Eastern Time. Interested participants can register for the presentation via this link.
Electromed, Inc. (AMEX: ELMD) announced its financial results for the fiscal 2022 third quarter, ending March 31, 2022, will be released on May 10, 2022, after market close. A conference call to discuss these results will follow at 5:00 p.m. Eastern Time on the same day. Participants can join by dialing specific numbers provided in the release. For those unable to attend, a replay will be available via phone and online.
Electromed, Inc. has appointed Christopher Holland as Chief Commercial Officer to spearhead its strategic growth initiatives. With 30 years of experience in the Medical Technology sector, Holland previously held significant roles at Prosomnus Sleep Technologies and Nonin Medical, where he drove substantial revenue growth. CEO Kathleen Skarvan expressed confidence in Holland's ability to enhance marketing and sales strategies that align with the company’s revenue goals and shareholder value. This leadership shift aims to position Electromed prominently within the airway clearance market.
Electromed, Inc. (NYSE American: ELMD) reported record quarterly net revenues of $10.2 million for the fiscal second quarter ended December 31, 2021, up from $9.5 million year-over-year. Home care revenues drove this growth, totaling $9.4 million, despite a decline in gross profit margin to 76.9% due to rising raw material and shipping costs. Operating income decreased to $1.1 million, with net income at $0.8 million or $0.10 per diluted share. The company plans to continue strategic growth initiatives, including a focus on expanding its sales force and developing new product offerings.
Electromed, Inc. (AMEX: ELMD) announced that it will release its financial results for the fiscal 2022 second quarter, ending December 31, 2021, on February 8, 2022, after the market closes. A conference call to discuss these results will be held at 5:00 p.m. ET on the same day, accessible via phone for domestic and international callers. The event can also be streamed live on the Investor Relations section of their website.
Electromed, a leader in airway clearance technologies, announced its participation in the Sidoti December Virtual Micro Cap Investor Conference on December 8-9, 2021. Key executives, including President Kathleen Skarvan and CFO Mike MacCourt, will present on December 8 at 2:30 p.m. Eastern Time and will be available for one-on-one meetings. Electromed is known for its SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function. The Company is based in New Prague, Minnesota, and has been operational since 1992.
Electromed, Inc. (NYSE American: ELMD) reported a record quarterly revenue of $10.0 million for Q1 FY 2022, reflecting a 25.0% increase year-over-year. Growth was driven by a 24.4% rise in home care revenue to $9.3 million and a 61.5% increase in institutional revenue. Gross profit margin improved to 77.0% despite rising costs. However, net income declined to $439,000 or $0.05 per diluted share. SG&A expenses rose to $6.8 million due to strategic investments. The company maintains $11.0 million in cash and continues to focus on product development and digital marketing strategies.
FAQ
What is the current stock price of Electromed (ELMD)?
What is the market cap of Electromed (ELMD)?
What does Electromed, Inc. do?
What conditions does the SmartVest® Airway Clearance System help with?
What is High-Frequency Chest Wall Oscillation (HFCWO)?
Is Electromed, Inc. certified?
What are the components of the SmartVest® System?
Where is Electromed, Inc. based?
How does the SmartVest® improve patient health?
Where can I find the latest news about Electromed, Inc.?
Does Electromed, Inc. operate worldwide?
What is the goal of Electromed, Inc.?
